Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

Lauren Shih¹, Megan Othus², Kelda Schonhoff¹, Carole Shaw³, Jacob Appelbaum¹, Anna B Halpern^{1

3}, Pamela S Becker^{1

4}, Roland B Walter^{1

3

5

6}, Elihu Estey^{1

3}, Mary-Elizabeth Percival^{7

8}

Affiliations

¹ Department of Medicine, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
⁵ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
⁶ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁷ Department of Medicine, University of Washington, Seattle, WA, USA. mperciva@uw.edu.
⁸ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. mperciva@uw.edu.

Lauren Shih et al. Leukemia. 2023 Sep.

. 2023 Sep;37(9):1912-1914.

doi: 10.1038/s41375-023-01981-2. Epub 2023 Jul 31.

¹ Department of Medicine, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
⁵ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
⁶ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁷ Department of Medicine, University of Washington, Seattle, WA, USA. mperciva@uw.edu.
⁸ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. mperciva@uw.edu.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

1. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. doi: 10.1182/blood.2022016867. - DOI - PubMed
1. Chen X, Xie H, Wood BL, Walter RB, Pagel JM, Becker PS, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258–64. doi: 10.1200/JCO.2014.58.3518. - DOI - PubMed
1. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–33. doi: 10.1056/NEJMoa1507471. - DOI - PubMed
1. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67. doi: 10.1182/blood.2021013626. - DOI - PMC - PubMed
1. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813–21. doi: 10.1182/blood-2013-06-506725. - DOI - PMC - PubMed